Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability - Fallahi-Sichani, Mohammad; Flynn, JoAnne L; Linderman, Jennifer J; Kirschner, Denise E (The Journal of immunology (1950), 2012)
Keywords: Adalimumab; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - blood; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - blood; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antirheumatic Agents - adverse effects; Antirheumatic Agents - blood; Antirheumatic Agents - classification; Antirheumatic Agents - pharmacokinetics; Apoptosis - drug effects; Certolizumab Pegol; Computer Simulation; Cytotoxicity, Immunologic; Etanercept; Humans; Immunoglobulin Fab Fragments - adverse effects; Immunoglobulin Fab Fragments - blood; Immunoglobulin G - adverse effects; Immunoglobulin G - blood; Infliximab; Latent Tuberculosis - immunology; Latent Tuberculosis - physiopathology; Models, Biological; Mycobacterium; Mycobacterium tuberculosis - growth & development; Mycobacterium tuberculosis - immunology; Permeability; Polyethylene Glycols - adverse effects; Polyethylene Glycols - pharmacokinetics; Protein Binding; Receptors, Tumor Necrosis Factor - blood; Receptors, Tumor Necrosis Factor - drug effects; Receptors, Tumor Necrosis Factor - physiology; Risk; Tuberculoma - immunology; Tuberculoma - microbiology; Tuberculoma - physiopathology; Tuberculosis, Pulmonary - immunology; Tuberculosis, Pulmonary - physiopathology; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - physiology